Fig. 5

VeroE6 cells were pre-treated with TL1228 compound (30 and 40 µM) for 1 h and inoculated with pseudotypes particles bearing the S proteins of the indicated variants A (Omicron BA.4/5) and B (Omicron BQ1.1) for 24 h and then analyzed. Infection efficiency was quantified by measuring virus-encoded luciferase activity in cell lysates after 24 h from Pseudovirus removal and expressed as percentage. Data presented are the average from three biological replicates. Error bars indicate the standard deviation ± SD. * p < 0.05, ** p < 0.01. Each value was normalized with respect to VSV_Pseudo SARS-CoV-2 S alone. Calu-3 cells were treated previously with TL1228 compound (40 µM) for 1 h and inoculated with pseudotypes particles bearing the S proteins of the indicated variants C (Omicron BQ1.1) and D (Omicron XBB.1.5) for 24 h and then analyzed. Infection efficiency was quantified by measuring virus encoded luciferase activity in cell lysates after 24 h from Pseudovirus removal and expressed as percentage. Data presented are the average from three biological replicates. Error bars indicate the standard deviation ± SD. * p < 0.05, ** p < 0.01. Each value was normalized with respect to VSV_Pseudo SARS-CoV-2 S alone. E The instrument used for vaporization of TL1228 compound 200 µM and 600 µM. F Calu-3 cells infection with VSV-Pseudo-SARS-CoV-2 S Omicron XBB.1.5 and treatment with vaporization of TL1228 compound 200 µM and 600 µM